Synergy Pharmaceuticals, Inc.s in-depth stock price analysis indicates that the stock price has rallied 10.38% in the past 12 Weeks , but analyzing the 6 month charts for the stock , the price continues to stay positive and keep the rally at 31.56% . Looking at the past 52 week period, the stock price is up at 71.39% . Relative price strength is a important factor used by wealth management firms while investing in stocks because the indicator compares the stock performance with the overall market. The relative price strength of Synergy Pharmaceuticals, Inc. has a positive value of 120.65 compared to overall market. Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) has tumbled 3.89% during the past week and has dropped 8.32% in the last 4 week period. The stocks are negative as compared to the S&P 500 for the past week with a loss of 4.67%. Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) has underperformed the index by 9.96% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) stock ended Friday session in the red zone in a volatile trading. The stock closed down 0.09 points or 1.44% at $6.17 with 4,755,696 shares getting traded. Post opening the session at $6.25, the shares hit an intraday low of $6.13 and an intraday high of $6.28 and the price was in this range throughout the day. The company has a market cap of $1,110 million and the number of outstanding shares has been calculated to be 179,953,610 shares. The 52-week high of Synergy Pharmaceuticals, Inc. (NASDAQ:SGYP) is $7.15 and the 52-week low is $2.5.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Company shares were Reiterated by Rodman & Renshaw on Jan 20, 2017 to Buy, Raises Price Target to $ 18 from a previous price target of $17 .Synergy Pharmaceuticals Inc was Initiated by Oppenheimer to Outperform on Jan 5, 2017. Company shares were Reiterated by Rodman & Renshaw on Dec 23, 2016 to Buy, Raises Price Target to $ 17 from a previous price target of $16 .
Company has reported several Insider transactions to the SEC, on Nov 8, 2016, & Co. Inc. Paulson (10% owner) sold 140,000 shares at 4.24 per share price.On Sep 21, 2016, John P Brancaccio (director) sold 2,518 shares at 5.76 per share price.On Sep 16, 2015, Bernard Denoyer (Senior Vice President, Finance) sold 10,000 shares at 7.50 per share price.
Synergy Pharmaceuticals, Inc. is a biopharmaceutical company focused primarily on the development of drugs to treat gastrointestinal disorders and diseases. Its lead drug candidate plecanatide is a guanylyl cyclase C receptor agonist, to treat GI disorders, primarily chronic constipation and constipation-predominant- irritable bowel syndrome. It is also engaged in developing receptor agonist for the treatment of gastrointestinal inflammatory diseases, such as ulcerative colitis. Synergy Pharmaceuticals, Inc. is headquartered in New York, New York.